Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05027867
Other study ID # KRT-232-112
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date December 6, 2021
Est. completion date August 26, 2022

Study information

Verified date August 2023
Source Kartos Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date August 26, 2022
Est. primary completion date August 26, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of SCLC documented as TP53WT - Disease must be measurable per RECIST Version 1.1 - Evidence of radiographic progression during or after at least one prior platinum-containing therapy with no curative therapy available. Subjects who have received only one prior line of therapy must not be candidates for platinum-based regimens at relapse. - Subjects must have received a checkpoint inhibitor (PD-1 or PD-L1) unless contraindicated if checkpoint inhibitors are approved and available. - ECOG = 2 Exclusion Criteria: - Symptomatic or uncontrolled central nervous system (CNS) metastases. - Prior treatment with MDM2 inhibitors - Chemotherapy, immune therapy, cytokine therapy, or any investigational therapy within 14 days prior to the first dose of study treatment - Grade 2 or higher QTc prolongation (> 480 milliseconds per NCI-CTCAE criteria, version 5.0) - History of major organ transplant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KRT-232
Administered by mouth

Locations

Country Name City State
Australia Flinders Medical Centre Bedford Park South Australia
France Edog - Ico - Ppds Angers Maine-et-Loire
France EDOG - Institut Bergonie - PPDS Bordeaux
France Hôpital Louis Pradel Bron Rhône
France CHU de Grenoble Grenoble
France Hospices Civils de Lyon Lyon Rhône
France Hopital Nord AP-HM Marseille
France Centre Hospitalier de Mulhouse - Hopital Emile Muller Mulhouse France/Haut-Rhin
France Hôpital de La Croix Rousse Pierre-Bénite Rhône
Germany Evangelische Lungenklinik Berlin Berlin
Germany Klinik für Kardiologie, Angiologie und Pneumologie Esslingen am Neckar Baden-Württemberg
Germany Lungenfachklinik Immenhausen Immenhausen Hessen
Hungary Bacs Kiskun Megyei Korhaz Kecskemét Bács-Kiskun
Korea, Republic of Chungbuk National University Hospital Cheongju-si Chungcheongbuk-do
Korea, Republic of CHA Bundang Medical Center, CHA University Seongnam-si Gyeonggido
Spain Hospital General Universitario de Alicante Alicante
Spain Hospital Universitario 12 de Octubre Alicante
Spain Hospital Universitario Vall d'Hebrón - PPDS Barcelona
Spain Clinica Universidad Navarra - Madrid Madrid
Spain Hospital Universitario La Paz Madrid
Spain Hospital Regional Universitario de Malaga - Hospital Civil Málaga
Spain Clinica Universidad Navarra Pamplona Navarra
Spain Hospital Universitario Virgen Macarena Sevilla
Spain Hospital Universitari i Politecnic La Fe de Valencia Valencia
United States Hematology Oncology Clinic Baton Rouge Louisiana
United States SCRI Tennessee Oncology Chattanooga Chattanooga Tennessee
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States Mark H Zangmeister Center - 3100 Plaza Properties Boulevard Columbus Ohio
United States Florida Cancer Specialists - 3840 Broadway Fort Myers Florida
United States Northwest Georgia Oncology Centers Marietta Georgia
United States SCRI Tennessee Oncology Nashville Nashville Tennessee
United States Florida Cancer Specialists - 560 Jackson St, Suite 220 Saint Petersburg Florida
United States Florida Cancer Specialists West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Kartos Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Australia,  France,  Germany,  Hungary,  Korea, Republic of,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) of each arm The proportion of subjects achieving partial response or better per RECIST 1.1 24 weeks
Secondary Duration of response (DOR) of each arm Time from initiation of response to disease progression or death 1 year
Secondary Progression-free survival (PFS) of each arm Time from first dose to disease progression or death 1 year
Secondary Overall survival (OS) of each arm Time from first dose to death 1 year
Secondary Disease control rate (DCR) of each arm The proportion of subjects achieving stable disease or better per RECIST 1.1 24 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05552846 - Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy Phase 2
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT04923776 - Liver Directed RT + Chemo-immunotherapy for ES-SCLC Phase 2
Recruiting NCT04168281 - Watchful Observation of Patients With LD-SCLC Instead of the PCI N/A
Completed NCT03239171 - Bioinformation Therapy for Lung Cancer Phase 2/Phase 3
Recruiting NCT06457906 - SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC Phase 3
Recruiting NCT04539977 - PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer Phase 2
Completed NCT03345485 - Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06103682 - LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE) N/A
Recruiting NCT04170946 - Talazoparib and Thoracic RT for ES-SCLC Phase 1
Recruiting NCT03523234 - Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage N/A
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Recruiting NCT05578326 - Study of Trilaciclib and Lurbinectidin Phase 2
Recruiting NCT06255197 - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Terminated NCT04610658 - Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Phase 1
Active, not recruiting NCT04116320 - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Phase 1
Active, not recruiting NCT05091567 - A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer Phase 3
Terminated NCT04596033 - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy Phase 1